Co-Authors
This is a "connection" page, showing publications co-authored by SHARON HERMES GIORDANO and KAREN H LU.
Connection Strength
0.646
-
Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. Gynecol Oncol. 2018 09; 150(3):451-459.
Score: 0.160
-
Determination of quality of life-related health utilities for surgical complications in ovarian cancer. Gynecol Oncol. 2024 06; 185:101-107.
Score: 0.059
-
Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. Gynecol Oncol. 2021 06; 161(3):653-659.
Score: 0.048
-
Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer. Am J Obstet Gynecol. 2021 07; 225(1):68.e1-68.e11.
Score: 0.048
-
National trends in bowel and upper abdominal procedures in ovarian cancer surgery. Int J Gynecol Cancer. 2020 08; 30(8):1195-1202.
Score: 0.046
-
Body mass index and attitudes towards health behaviors among women with endometrial cancer before and after treatment. Int J Gynecol Cancer. 2020 02; 30(2):187-192.
Score: 0.044
-
Total and out-of-pocket costs of different primary management strategies in ovarian cancer. Am J Obstet Gynecol. 2019 08; 221(2):136.e1-136.e9.
Score: 0.042
-
National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer. Gynecol Oncol. 2019 03; 152(3):439-444.
Score: 0.042
-
Disparities in treatment and survival among elderly ovarian cancer patients. Gynecol Oncol. 2018 11; 151(2):269-274.
Score: 0.041
-
Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstet Gynecol. 2018 07; 132(1):52-58.
Score: 0.040
-
Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. Int J Gynecol Cancer. 2017 09; 27(7):1350-1359.
Score: 0.038
-
Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecol Oncol. 2017 04; 145(1):55-60.
Score: 0.036